Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Cidara Therapeutics ( (CDTX) ) has shared an update.
Cidara Therapeutics announced key leadership changes with the resignation of board member Laura Tadvalkar, Ph.D., and the mutual separation of Chief Medical Officer Taylor Sandison, M.D., M.P.H., to be effective on February 3, 2025. Nicole Davarpanah, M.D., J.D., will assume interim Chief Medical Officer responsibilities. Additionally, Josh Resnick, M.D., was appointed as a Class II board member, with his term expiring at the 2026 annual stockholder meeting. His compensation package includes an annual cash retainer and stock option grants, underlining Cidara’s commitment to strengthen its governance and strategic direction.
More about Cidara Therapeutics
YTD Price Performance: -1.79%
Average Trading Volume: 59,412
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $293.4M
For a thorough assessment of CDTX stock, go to TipRanks’ Stock Analysis page.
